Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Indian Journal of Surgical Oncology
Published in: Indian Journal of Surgical Oncology 1/2017

01-03-2017 | Review Article

Molecular and Functional Diagnostic Tools in Precision Oncology for Urological Malignancies

Authors: Vasanthakumar Sekar, Debapriya Ghosh Mehrotra, Biswanath Majumder

Published in: Indian Journal of Surgical Oncology | Issue 1/2017

Login to get access

Abstract

Urological malignancies, represented mainly by prostate, bladder, and renal cancers, are some of the leading causes of cancer-related mortalities worldwide. Despite various efforts over decades to develop early detection tests and effective therapeutic paradigms, the response rate to the existing treatments remains low for both primary and late stage/recurrent phases of these cancers. The evolving landscape of molecular diagnostics, aiming to make the diagnosis and treatment more patient-driven, underpins precision oncology and particularly intends to rationally profile individual tumors and highlight the mechanistic insight and complexity of tumor microenvironment in order to develop biomarkers of toxicity risks and response prediction in a clinically oriented dynamical setting. The present review is an effort to capture some of the recent developments in the area of molecular diagnostics and functional testing platforms and their potential application in clinical decision making in the premises of precision oncology of urological malignancies.
Literature
1.
Zeigler-Johnson CM, Rennert H, Mittal RD, Jalloh M, Sachdeva R, Malkowicz SB et al (2008) Evaluation of prostate cancer characteristics in four populations worldwide. Can J Urol 15:4056–4064PubMedPubMedCentral
2.
Botteman MF, Pashos CL, Redaelli A, Laskin B, Hauser R (2003) The health economics of bladder cancer: a comprehensive review of the published literature. PharmacoEconomics 21:1315–1330CrossRefPubMed
3.
Moyer VA (2012) Screening for prostate cancer: U.S. preventive services task force recommendation statement. Ann Intern Med 157:120–134CrossRefPubMed
4.
5.
Barry MJ (2001) Clinical practice. Prostate-specific-antigen testing for early diagnosis of prostate cancer. N Engl J Med 344:1373–1377CrossRefPubMed
6.
Tomlins SA, Laxman B, Varambally S, Cao X, Yu J, Helgeson BE et al (2008) Role of the TMPRSS2-ERG gene fusion in prostate cancer. Neoplasia 10:177–188CrossRefPubMedPubMedCentral
7.
Goodison S, Rosser CJ, Urquidi V (2013) Bladder cancer detection and monitoring: assessment of urine- and blood-based marker tests. Mol Diagn Ther 17:71–84CrossRefPubMedPubMedCentral
8.
9.
Hoadley KA, Yau C, Wolf DM, Cherniack AD, Tamborero D, Ng S et al (2014) Multiplatform analysis of 12 cancer types reveals molecular classification within and across tissues of origin. Cell 158:929–944CrossRefPubMedPubMedCentral
10.
Takahashi M, Yang XJ, Sugimura J, Backdahl J, Tretiakova M, Qian CN et al (2003) Molecular subclassification of kidney tumors and the discovery of new diagnostic markers. Oncogene 22:6810–6818CrossRefPubMed
11.
Gundem G, Van Loo P, Kremeyer B, Alexandrov LB, Tubio JM, Papaemmanuil E et al (2015) The evolutionary history of lethal metastatic prostate cancer. Nature 520:353–357CrossRefPubMedPubMedCentral
12.
Irshad S, Bansal M, Castillo-Martin M, Zheng T, Aytes A, Wenske S et al (2013) A molecular signature predictive of indolent prostate cancer. Sci Transl Med 5:202ra122CrossRefPubMedPubMedCentral
13.
Klein EA, Cooperberg MR, Magi-Galluzzi C, Simko JP, Falzarano SM, Maddala T et al (2014) A 17-gene assay to predict prostate cancer aggressiveness in the context of Gleason grade heterogeneity, tumor multifocality, and biopsy undersampling. Eur Urol 66:550–560CrossRefPubMed
14.
Erho N, Crisan A, Vergara IA, Mitra AP, Ghadessi M, Buerki C et al (2013) Discovery and validation of a prostate cancer genomic classifier that predicts early metastasis following radical prostatectomy. PLoS One 8:e66855CrossRefPubMedPubMedCentral
15.
Bishoff JT, Freedland SJ, Gerber L, Tennstedt P, Reid J, Welbourn W et al (2014) Prognostic utility of the cell cycle progression score generated from biopsy in men treated with prostatectomy. J Urol 192:409–414CrossRefPubMed
16.
Spahn M, Boxler S, Joniau S, Moschini M, Tombal B, Karnes RJ (2015) What is the need for prostatic biomarkers in prostate cancer management? Curr Urol Rep 16:545CrossRef
17.
Ponsky LE, Sharma S, Pandrangi L, Kedia S, Nelson D, Agarwal A et al (2001) Screening and monitoring for bladder cancer: refining the use of NMP22. J Urol 166:75–78CrossRefPubMed
18.
Gutierrez Banos JL, del Henar Rebollo Rodrigo M, Antolin Juarez FM, Garcia BM (2001) Usefulness of the BTA STAT test for the diagnosis of bladder cancer. Urology 57(4):685–689CrossRefPubMed
19.
Greene KL, Berry A, Konety BR (2006) Diagnostic utility of the ImmunoCyt/uCyt+ test in bladder cancer. Rev Urol 8:190–197PubMedPubMedCentral
20.
Li HX, Li M, Li CL, Ma JH, Wang MR, Rao J et al (2010) ImmunoCyt and cytokeratin 20 immunocytochemistry as adjunct markers for urine cytologic detection of bladder cancer: a prospective study. Anal Quant Cytol Histol 32:45–52PubMed
21.
Laudadio J, Keane TE, Reeves HM, Savage SJ, Hoda RS, Lage JM et al (2005) Fluorescence in situ hybridization for detecting transitional cell carcinoma: implications for clinical practice. BJU Int 96:1280–1285CrossRefPubMed
22.
Stephenson AJ, Smith A, Kattan MW, Satagopan J, Reuter VE, Scardino PT et al (2005) Integration of gene expression profiling and clinical variables to predict prostate carcinoma recurrence after radical prostatectomy. Cancer 104:290–298CrossRefPubMedPubMedCentral
23.
Netto GJ (2011) Molecular diagnostics in urologic malignancies: a work in progress. Arch Pathol Lab Med 135:610–621PubMed
24.
Schalken J, Dijkstra S, Baskin-Bey E, van Oort I (2014) Potential utility of cancer-specific biomarkers for assessing response to hormonal treatments in metastatic prostate cancer. Ther Adv Urol 6:245–252CrossRefPubMedPubMedCentral
25.
Mackey TJ, Borkowski A, Amin P, Jacobs SC, Kyprianou N (1998) Bcl-2/bax ratio as a predictive marker for therapeutic response to radiotherapy in patients with prostate cancer. Urology 52:1085–1090CrossRefPubMed
26.
Atkins M, Regan M, McDermott D, Mier J, Stanbridge E, Youmans A et al (2005) Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer. Clin Cancer Res 11:3714–3721CrossRefPubMed
27.
Kohli M, Young CY, Tindall DJ, Nandy D, McKenzie KM, Bevan GH et al (2015) Whole blood defensin mRNA expression is a predictive biomarker of docetaxel response in castration-resistant prostate cancer. Onco Targets Ther 8:1915–1922PubMedPubMedCentral
28.
Ibeawuchi C, Schmidt H, Voss R, Titze U, Abbas M, Neumann J et al (2015) Exploring prostate cancer genome reveals simultaneous losses of PTEN, FAS and PAPSS2 in patients with PSA recurrence after radical prostatectomy. Int J Mol Sci 16:3856–3869CrossRefPubMedPubMedCentral
29.
Thomas GV, Horvath S, Smith BL, Crosby K, Lebel LA, Schrage M et al (2004) Antibody-based profiling of the phosphoinositide 3-kinase pathway in clinical prostate cancer. Clin Cancer Res 10:8351–8356CrossRefPubMed
30.
Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A et al (2010) Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376:687–697CrossRefPubMed
31.
Ploussard G, Terry S, Maille P, Allory Y, Sirab N, Kheuang L et al (2010) Class III beta-tubulin expression predicts prostate tumor aggressiveness and patient response to docetaxel-based chemotherapy. Cancer Res 70:9253–9264CrossRefPubMedPubMedCentral
32.
He F, Melamed J, Tang MS, Huang C, Wu XR (2015) Oncogenic HRAS activates epithelial-to-mesenchymal transition and confers stemness to p53-deficient urothelial cells to drive muscle invasion of basal subtype carcinomas. Cancer Res 75:2017–2028CrossRefPubMedPubMedCentral
33.
Church D, Kerr R, Domingo E, Rosmarin D, Palles C, Maskell K et al (2014) 'Toxgnostics': an unmet need in cancer medicine. Nat Rev Cancer 14:440–445CrossRefPubMed
34.
Svensson JP, Stalpers LJ, Esveldt-van Lange RE, Franken NA, Haveman J, Klein B et al (2006) Analysis of gene expression using gene sets discriminates cancer patients with and without late radiation toxicity. PLoS Med 3:e422CrossRefPubMedPubMedCentral
35.
Hummerich J, Werle-Schneider G, Popanda O, Celebi O, Chang-Claude J, Kropp S et al (2006) Constitutive mRNA expression of DNA repair-related genes as a biomarker for clinical radio-resistance: a pilot study in prostate cancer patients receiving radiotherapy. Int J Radiat Biol 82:593–604CrossRefPubMed
36.
Garcia-Donas J, Esteban E, Leandro-Garcia LJ, Castellano DE, del Alba AG, Climent MA et al (2011) Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: a multicentre, observational, prospective study. Lancet Oncol 12:1143–1150CrossRefPubMed
37.
Widakowich C, de Castro G Jr, de Azambuja E, Dinh P, Awada A (2007) Review: side effects of approved molecular targeted therapies in solid cancers. Oncologist 12:1443–1455CrossRefPubMed
38.
Ciccolini J, Gross E, Dahan L, Lacarelle B, Mercier C (2010) Routine dihydropyrimidine dehydrogenase testing for anticipating 5-fluorouracil-related severe toxicities: hype or hope? Clin Colorectal Cancer 9:224–228CrossRefPubMed
39.
Calhoun EA, Chang CH, Welshman EE, Fishman DA, Lurain JR, Bennett CL (2001) Evaluating the total costs of chemotherapy-induced toxicity: results from a pilot study with ovarian cancer patients. Oncologist 6:441–445CrossRefPubMed
40.
Yoshida T, Kinoshita H, Segawa T, Nakamura E, Inoue T, Shimizu Y et al (2005) Antiandrogen bicalutamide promotes tumor growth in a novel androgen-dependent prostate cancer xenograft model derived from a bicalutamide-treated patient. Cancer Res 65:9611–9616CrossRefPubMed
41.
Bohl CE, Gao W, Miller DD, Bell CE, Dalton JT (2005) Structural basis for antagonism and resistance of bicalutamide in prostate cancer. Proc Natl Acad Sci U S A 102:6201–6206CrossRefPubMedPubMedCentral
42.
Fenton MA, Shuster TD, Fertig AM, Taplin ME, Kolvenbag G, Bubley GJ et al (1997) Functional characterization of mutant androgen receptors from androgen-independent prostate cancer. Clin Cancer Res 3:1383–1388PubMed
43.
Bohl CE, Wu Z, Miller DD, Bell CE, Dalton JT (2007) Crystal structure of the T877A human androgen receptor ligand-binding domain complexed to cyproterone acetate provides insight for ligand-induced conformational changes and structure-based drug design. J Biol Chem 282:13648–13655CrossRefPubMedPubMedCentral
44.
Steinestel J, Luedeke M, Arndt A, Schnoeller TJ, Lennerz JK, Wurm C, et al. (2015) Detecting predictive androgen receptor modifications in circulating prostate cancer cells. Oncotarget
45.
46.
Sharma SV, Lee DY, Li B, Quinlan MP, Takahashi F, Maheswaran S et al (2010) A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell 141(1):69–80CrossRefPubMedPubMedCentral
47.
Goldman A, Majumder B, Dhawan A, Ravi S, Goldman D, Kohandel M et al (2015) Temporally sequenced anticancer drugs overcome adaptive resistance by targeting a vulnerable chemotherapy-induced phenotypic transition. Nat Commun 6:6139CrossRefPubMedPubMedCentral
48.
Majumder B, Baraneedharan U, Thiyagarajan S, Radhakrishnan P, Narasimhan H, Dhandapani M et al (2015) Predicting clinical response to anticancer drugs using an ex vivo platform that captures tumour heterogeneity. Nat Commun 6:6169CrossRefPubMedPubMedCentral
49.
Van Allen EM, Lui VW, Egloff AM, Goetz EM, Li H, Johnson JT et al (2015) Genomic correlate of exceptional erlotinib response in head and neck squamous cell carcinoma. JAMA Oncol 1:238–244CrossRefPubMedPubMedCentral
50.
Peters S, Michielin O, Zimmermann S (2013) Dramatic response induced by vemurafenib in a BRAF V600E-mutated lung adenocarcinoma. J Clin Oncol 31:e341–e344CrossRefPubMed
51.
Su F, Viros A, Milagre C, Trunzer K, Bollag G, Spleiss O et al (2012) RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N Engl J Med 366:207–215CrossRefPubMedPubMedCentral
52.
Ercan D, Xu C, Yanagita M, Monast CS, Pratilas CA, Montero J et al (2012) Reactivation of ERK signaling causes resistance to EGFR kinase inhibitors. Cancer Discov 2:934–947CrossRefPubMedPubMedCentral
53.
Gerlinger M, Horswell S, Larkin J, Rowan AJ, Salm MP, Varela I et al (2014) Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing. Nat Genet 46:225–233CrossRefPubMedPubMedCentral
54.
Boutros PC, Fraser M, Harding NJ, de Borja R, Trudel D, Lalonde E et al (2015) Spatial genomic heterogeneity within localized, multifocal prostate cancer. Nat Genet 47:736–745CrossRefPubMed
55.
Junttila MR, de Sauvage FJ (2013) Influence of tumour micro-environment heterogeneity on therapeutic response. Nature 501:346–354CrossRefPubMed
56.
Collins KB, Patterson BK, Naus GJ, Landers DV, Gupta P (2000) Development of an in vitro organ culture model to study transmission of HIV-1 in the female genital tract. Nat Med 6:475–479CrossRefPubMed
57.
58.
Shamir ER, Ewald AJ (2014) Three-dimensional organotypic culture: experimental models of mammalian biology and disease. Nat Rev Mol Cell Biol 15:647–664CrossRefPubMedPubMedCentral
59.
Gupta PB, Onder TT, Jiang G, Tao K, Kuperwasser C, Weinberg RA et al (2009) Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell 138:645–659CrossRefPubMedPubMedCentral
60.
Kenny HA, Lal-Nag M, White EA, Shen M, Chiang CY, Mitra AK et al (2015) Quantitative high throughput screening using a primary human three-dimensional organotypic culture predicts in vivo efficacy. Nat Commun 6:6220CrossRefPubMedPubMedCentral
61.
Ginestier C, Hur MH, Charafe-Jauffret E, Monville F, Dutcher J, Brown M et al (2007) ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 1:555–567CrossRefPubMedPubMedCentral
62.
McMillin DW, Delmore J, Weisberg E, Negri JM, Geer DC, Klippel S et al (2010) Tumor cell-specific bioluminescence platform to identify stroma-induced changes to anticancer drug activity. Nat Med 16:483–489CrossRefPubMedPubMedCentral
63.
Ridky TW, Chow JM, Wong DJ, Khavari PA (2010) Invasive three-dimensional organotypic neoplasia from multiple normal human epithelia. Nat Med 16:1450–1455CrossRefPubMedPubMedCentral
64.
Vaira V, Fedele G, Pyne S, Fasoli E, Zadra G, Bailey D et al (2010) Preclinical model of organotypic culture for pharmacodynamic profiling of human tumors. Proc Natl Acad Sci U S A 107:8352–8356CrossRefPubMedPubMedCentral
65.
Gerlach MM, Merz F, Wichmann G, Kubick C, Wittekind C, Lordick F et al (2014) Slice cultures from head and neck squamous cell carcinoma: a novel test system for drug susceptibility and mechanisms of resistance. Br J Cancer 110:479–488CrossRefPubMed
66.
Brouzes E, Medkova M, Savenelli N, Marran D, Twardowski M, Hutchison JB et al (2009) Droplet microfluidic technology for single-cell high-throughput screening. Proc Natl Acad Sci U S A 106:14195–14200CrossRefPubMedPubMedCentral
67.
Hirt C, Papadimitropoulos A, Mele V, Muraro MG, Mengus C, Iezzi G et al (2014) "In vitro" 3D models of tumor-immune system interaction. Adv Drug Deliv Rev 79:145–154CrossRefPubMed
68.
Weiswald LB, Richon S, Validire P, Briffod M, Lai-Kuen R, Cordelieres FP et al (2009) Newly characterised ex vivo colospheres as a three-dimensional colon cancer cell model of tumour aggressiveness. Br J Cancer 101:473–482CrossRefPubMedPubMedCentral
69.
Collins AT, Berry PA, Hyde C, Stower MJ, Maitland NJ (2005) Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res 65:10946–10951CrossRefPubMed
70.
Brockman JA, Alanee S, Vickers AJ, Scardino PT, Wood DP, Kibel AS et al (2015) Nomogram predicting prostate cancer-specific mortality for men with biochemical recurrence after radical prostatectomy. Eur Urol 67:1160–1167CrossRefPubMed
71.
Gao D, Vela I, Sboner A, Iaquinta PJ, Karthaus WR, Gopalan A et al (2014) Organoid cultures derived from patients with advanced prostate cancer. Cell 159:176–187CrossRefPubMedPubMedCentral
72.
Swanton C, Larkin JM, Gerlinger M, Eklund AC, Howell M, Stamp G et al (2010) Predictive biomarker discovery through the parallel integration of clinical trial and functional genomics datasets. Genome Med 2:53CrossRefPubMedPubMedCentral
73.
Jonas O, Landry HM, Fuller JE, Santini JT Jr, Baselga J, Tepper RI et al (2015) An implantable microdevice to perform high-throughput in vivo drug sensitivity testing in tumors. Sci Transl Med 7:284ra57CrossRefPubMedPubMedCentral
74.
Klinghoffer RA, Bahrami SB, Hatton BA, Frazier JP, Moreno-Gonzalez A, Strand AD et al (2015) A technology platform to assess multiple cancer agents simultaneously within a patient’s tumor. Sci Transl Med 7:284ra58
75.
Hofmann D, Nitz U, Gluz O, Kates RE, Schinkoethe T, Staib P et al (2013) WSG ADAPT—adjuvant dynamic marker-adjusted personalized therapy trial optimizing risk assessment and therapy response prediction in early breast cancer: study protocol for a prospective, multi-center, controlled, non-blinded, randomized, investigator initiated phase II/III trial. Trials 14:261CrossRefPubMedPubMedCentral
76.
Montero J, Sarosiek KA, DeAngelo JD, Maertens O, Ryan J, Ercan D et al (2015) Drug-induced death signaling strategy rapidly predicts cancer response to chemotherapy. Cell 160:977–989CrossRefPubMedPubMedCentral
77.
Bosserman L, Rogers K, Willis C, Davidson D, Whitworth P, Karimi M et al (2015) Application of a drug-induced apoptosis assay to identify treatment strategies in recurrent or metastatic breast cancer. PLoS One 10:e0122609CrossRefPubMedPubMedCentral
78.
Huang Q, Li F, Liu X, Li W, Shi W, Liu FF et al (2011) Caspase 3-mediated stimulation of tumor cell repopulation during cancer radiotherapy. Nat Med 17:860–866CrossRefPubMedPubMedCentral
79.
80.
Janes H, Pepe MS, McShane LM, Sargent DJ, Heagerty PJ (2015) The fundamental difficulty with evaluating the accuracy of biomarkers for guiding treatment. J Natl Cancer Inst 107(8):djv157CrossRefPubMedPubMedCentral
81.
82.
Burstein HJ, Mangu PB, Somerfield MR, Schrag D, Samson D, Holt L et al (2011) American Society of Clinical Oncology clinical practice guideline update on the use of chemotherapy sensitivity and resistance assays. J Clin Oncol 29:3328–3330CrossRefPubMed
Metadata
Title
Molecular and Functional Diagnostic Tools in Precision Oncology for Urological Malignancies
Authors
Vasanthakumar Sekar
Debapriya Ghosh Mehrotra
Biswanath Majumder
Publication date
01-03-2017
Publisher
Springer India
Published in
Indian Journal of Surgical Oncology / Issue 1/2017
Print ISSN: 0975-7651
Electronic ISSN: 0976-6952
DOI
https://doi.org/10.1007/s13193-016-0591-4

Other articles of this Issue 1/2017

Indian Journal of Surgical Oncology 1/2017 Go to the issue

Review Article

VEIL Surgical Steps

Review Article

Organ Preservation Surgery for Carcinoma Penis

Original Article

Management of Bilateral Wilms’ Tumor: Our Experience

Review Article

Non-Surgical Ablative Therapy for Management of Small Renal Masses—Current Status and Future Trends

Review Article

Growing Teratoma Syndrome

Editorial

Desk of the Editor Vol.8 Issue 1